Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.

Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills RK, Russell NH, Osborne CS, Papaemmanuil E, Gottgens B, Campbell PJ, Huntly BJP.

Blood. 2019 Sep 12. pii: blood.2019001553. doi: 10.1182/blood.2019001553. [Epub ahead of print]

PMID:
31515253
2.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2019 Apr 19. pii: haematol.2018.208678. doi: 10.3324/haematol.2018.208678. [Epub ahead of print]

3.

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2019 Feb 28;9(3):28. doi: 10.1038/s41408-019-0190-z.

4.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

Christen F, Hoyer K, Yoshida K, Hou HA, Waldhueter N, Heuser M, Hills RK, Chan W, Hablesreiter R, Blau O, Ochi Y, Klement P, Chou WC, Blau IW, Tang JL, Zemojtel T, Shiraishi Y, Shiozawa Y, Thol F, Ganser A, Löwenberg B, Linch DC, Bullinger L, Valk PJM, Tien HF, Gale RE, Ogawa S, Damm F.

Blood. 2019 Mar 7;133(10):1140-1151. doi: 10.1182/blood-2018-05-852822. Epub 2019 Jan 4.

PMID:
30610028
5.

Real world data and the art of maintenance therapy.

Hills RK.

Br J Haematol. 2019 Feb;184(4):493-494. doi: 10.1111/bjh.15724. Epub 2018 Dec 27. No abstract available.

PMID:
30592028
6.

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.

Freeman SD, Hills RK, Russell NH; UK NCRI AML Trial Group, Cloos J, Kelder A, Ossenkoppele GJ, Schuurhuis GJ; HOVON AML Trial Group.

Br J Haematol. 2019 Jul;186(1):130-133. doi: 10.1111/bjh.15698. Epub 2018 Dec 5. No abstract available.

PMID:
30520018
7.

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. Erratum in: Blood Cancer J. 2019 Feb 28;9(3):28.

8.

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.

Burnett AK, Das Gupta E, Knapper S, Khwaja A, Sweeney M, Kjeldsen L, Hawkins T, Betteridge SE, Cahalin P, Clark RE, Hills RK, Russell NH; UK NCRI AML Study Group.

Haematologica. 2018 Oct;103(10):1654-1661. doi: 10.3324/haematol.2018.189514. Epub 2018 Jul 5.

9.

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.

Burnett AK, Hills RK, Nielsen OJ, Freeman S, Ali A, Cahalin P, Hunter A, Thomas IF, Russell NH.

Leukemia. 2018 Dec;32(12):2693-2714. doi: 10.1038/s41375-018-0148-3. Epub 2018 Jun 6. No abstract available.

PMID:
29875430
10.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Lucas CM, Scott LJ, Carmell N, Holcroft AK, Hills RK, Burnett AK, Clark RE.

Blood Adv. 2018 May 8;2(9):964-968. doi: 10.1182/bloodadvances.2017013615. No abstract available.

11.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH.

J Clin Oncol. 2018 May 20;36(15):1486-1497. doi: 10.1200/JCO.2017.76.3425. Epub 2018 Mar 30.

12.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

13.

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

Gale RE, Popa T, Wright M, Khan N, Freeman SD, Burnett AK, Russell NH, Hills RK, Linch DC.

Blood. 2018 Jan 25;131(4):468-471. doi: 10.1182/blood-2017-08-802157. Epub 2017 Dec 11. No abstract available.

14.

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

Voisset E, Moravcsik E, Stratford EW, Jaye A, Palgrave CJ, Hills RK, Salomoni P, Kogan SC, Solomon E, Grimwade D.

Blood. 2018 Feb 8;131(6):636-648. doi: 10.1182/blood-2017-07-794784. Epub 2017 Nov 30.

15.

Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.

El-Sharkawi D, Sproul D, Allen CG, Feber A, Wright M, Hills RK, Linch DC, Gale RE.

Haematologica. 2018 Jan;103(1):91-100. doi: 10.3324/haematol.2017.173096. Epub 2017 Oct 12.

16.

Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of PET in patients with oesophageal cancer.

Foley KG, Hills RK, Berthon B, Marshall C, Parkinson C, Lewis WG, Crosby TDL, Spezi E, Roberts SA.

Eur Radiol. 2018 Jan;28(1):428-436. doi: 10.1007/s00330-017-4973-y. Epub 2017 Aug 2.

17.

Telomere length is an independent prognostic marker in MDS but not in de novo AML.

Williams J, Heppel NH, Britt-Compton B, Grimstead JW, Jones RE, Tauro S, Bowen DT, Knapper S, Groves M, Hills RK, Pepper C, Baird DM, Fegan C.

Br J Haematol. 2017 Jul;178(2):240-249. doi: 10.1111/bjh.14666. Epub 2017 May 9.

PMID:
28486748
18.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

19.

Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia.

Chilton L, Harrison CJ, Ashworth I, Murdy D, Burnett AK, Grimwade D, Moorman AV, Hills RK.

Leukemia. 2017 May;31(5):1234-1237. doi: 10.1038/leu.2017.37. Epub 2017 Jan 23. No abstract available.

PMID:
28111469
20.

Non-inferiority trials: No better? No worse? No change? No pain?

Hills RK.

Br J Haematol. 2017 Mar;176(6):883-887. doi: 10.1111/bjh.14504. Epub 2017 Jan 20. Review.

PMID:
28106905
21.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK.

Blood. 2017 Mar 2;129(9):1143-1154. doi: 10.1182/blood-2016-07-730648. Epub 2016 Nov 21.

22.

Statistical reporting in the BJH: some dos and don'ts.

Hills RK.

Br J Haematol. 2017 Feb;176(3):345-351. doi: 10.1111/bjh.14426. Epub 2016 Nov 18. Review.

PMID:
27859002
23.

The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities.

Chilton L, Hills RK, Burnett AK, Harrison CJ.

Leukemia. 2016 Nov;30(11):2264-2267. doi: 10.1038/leu.2016.200. Epub 2016 Jul 25. No abstract available.

24.

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group.

Haematologica. 2016 Nov;101(11):1351-1358. Epub 2016 Aug 18.

25.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK, Freeman SD.

Leukemia. 2017 May;31(5):1059-1068. doi: 10.1038/leu.2016.309. Epub 2016 Oct 31.

26.

Treatment intensification in diffuse large B-Cell lymphoma: lessons for clinical trial design.

Hills RK.

Br J Haematol. 2016 Nov;175(4):555-556. doi: 10.1111/bjh.14400. Epub 2016 Oct 13. No abstract available.

PMID:
27734467
27.

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD.

PLoS One. 2016 Sep 26;11(9):e0163291. doi: 10.1371/journal.pone.0163291. eCollection 2016.

28.

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE.

Leukemia. 2017 Feb;31(2):310-317. doi: 10.1038/leu.2016.225. Epub 2016 Sep 2.

29.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Hills RK, Ivey A, Grimwade D; UK National Cancer Research Institute (NCRI) AML Working Group.

N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847. No abstract available.

PMID:
27509124
30.

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.

Burnett AK, Russell NH, Hills RK; United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group.

Blood. 2016 Jul 21;128(3):449-52. doi: 10.1182/blood-2016-04-712091. Epub 2016 Jun 6. No abstract available.

31.

The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.

Dickson GJ, Bustraan S, Hills RK, Ali A, Goldstone AH, Burnett AK, Linch DC, Gale RE.

Br J Haematol. 2016 Feb;172(4):573-80. doi: 10.1111/bjh.13873. Epub 2015 Dec 21.

32.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D; UK National Cancer Research Institute AML Working Group.

N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20.

33.

Cord Blood-Derived Quiescent CD34+ Cells Are More Transcriptionally Matched to AML Blasts Than Cytokine-Induced Normal Human Hematopoietic CD34+ Cells.

Munje C, Hills RK, Whetton A, Burnett AK, Darley RL, Tonks A.

Gene Expr. 2015;16(4):169-175. doi: 10.3727/105221615X14399878166159.

34.

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group.

Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.

PMID:
26384238
35.

Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.

Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, Tinsley S, Dickson G, Burnett AK, Hills RK, Linch DC.

J Clin Oncol. 2015 Jun 20;33(18):2072-83. doi: 10.1200/JCO.2014.59.2022. Epub 2015 May 11.

PMID:
25964253
36.

An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.

Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, Grech A, Vyas P, Grimwade D, Russell NH, Burnett AK, Hills RK.

Br J Haematol. 2015 Jul;170(1):80-4. doi: 10.1111/bjh.13398. Epub 2015 Apr 14.

PMID:
25876768
37.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group.

Blood. 2015 Jun 18;125(25):3878-85. doi: 10.1182/blood-2015-01-623447. Epub 2015 Apr 1.

38.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, Duprez E, Linch DC, Delwel R, Löwenberg B, Baldus CD, Solomon E, Burnett AK, Grimwade D.

Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.

39.

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK.

Blood. 2015 May 7;125(19):2923-32. doi: 10.1182/blood-2014-10-608117. Epub 2015 Mar 24.

40.

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.

Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D.

Leukemia. 2015 Jun;29(6):1312-9. doi: 10.1038/leu.2015.38. Epub 2015 Feb 13.

PMID:
25676423
41.

Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer.

Scurr MJ, Brown CM, Costa Bento DF, Betts GJ, Rees BI, Hills RK, Gallimore A, Godkin A.

J Natl Cancer Inst. 2015 Feb 9;107(4). pii: djv001. doi: 10.1093/jnci/djv001. Print 2015 Apr.

42.

A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia.

Russell NH, Kjeldsen L, Craddock C, Pagliuca A, Yin JA, Clark RE, Howman A, Hills RK, Burnett AK; UK NCRI Adult AML Working Party.

Leukemia. 2015 Jul;29(7):1478-84. doi: 10.1038/leu.2014.319. Epub 2014 Nov 7.

PMID:
25376374
43.

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, Appelbaum FR, Estey EH.

Leukemia. 2015 Feb;29(2):312-20. doi: 10.1038/leu.2014.242. Epub 2014 Aug 12.

44.

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK.

Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6. Review.

45.

Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?

Grimwade D, Jovanovic JV, Hills RK.

Best Pract Res Clin Haematol. 2014 Mar;27(1):53-61. doi: 10.1016/j.beha.2014.04.002. Epub 2014 Apr 12. Review.

PMID:
24907017
46.

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE.

Blood. 2014 Jul 10;124(2):273-6. doi: 10.1182/blood-2014-02-554667. Epub 2014 May 22.

47.

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial.

Lazenby M, Gilkes AF, Marrin C, Evans A, Hills RK, Burnett AK.

Leukemia. 2014 Oct;28(10):1953-9. doi: 10.1038/leu.2014.90. Epub 2014 Feb 27.

PMID:
24573385
48.

Who is an "older" patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials.

Mohamed I, Hills RK, Burnett AK.

Br J Haematol. 2014 Apr;165(1):147-51. doi: 10.1111/bjh.12705. Epub 2013 Dec 23. No abstract available.

PMID:
24372387
49.

The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts.

Zabkiewicz J, Pearn L, Hills RK, Morgan RG, Tonks A, Burnett AK, Darley RL.

Haematologica. 2014 May;99(5):858-64. doi: 10.3324/haematol.2013.096487. Epub 2013 Dec 13.

50.

Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling.

Hole PS, Zabkiewicz J, Munje C, Newton Z, Pearn L, White P, Marquez N, Hills RK, Burnett AK, Tonks A, Darley RL.

Blood. 2013 Nov 7;122(19):3322-30. doi: 10.1182/blood-2013-04-491944. Epub 2013 Oct 2.

Supplemental Content

Loading ...
Support Center